Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
about
Fast disintegrating tablets: Opportunity in drug delivery systemDrug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxisMiltefosine Lipid Nanocapsules for Single Dose Oral Treatment of Schistosomiasis Mansoni: A Preclinical StudyEffect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel.Study on biopharmaceutics classification and oral bioavailability of a novel multikinase inhibitor NCE for cancer therapy.The use of biorelevant dissolution media to forecast the in vivo performance of a drug.Triethanolamine stabilization of methotrexate-β-cyclodextrin interactions in ternary complexes.Predictive approaches to increase absorption of compounds during lead optimisation.Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness.An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.Evaluation of the use of partition coefficients and molecular surface properties as predictors of drug absorption: a provisional biopharmaceutical classification of the list of national essential medicines of Pakistan.Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection.Molecular dynamics simulations of large macromolecular complexes.Using a single tablet daily to treat latent tuberculosis infection in Brazil: bioequivalence of two different isoniazid formulations (300 mg and 100 mg) demonstrated by a sensitive and rapid high-performance liquid chromatography-tandem mass spectroImpact of vibration and agitation speed on dissolution of USP prednisone tablets RS and various IR tablet formulations.A menthol-based solid dispersion technique for enhanced solubility and dissolution of sulfamethoxazole from an oral tablet matrix.Stability-enhanced hot-melt extruded amorphous solid dispersions via combinations of Soluplus® and HPMCAS-HF.Characterization of ibuprofen microparticle and improvement of the dissolution.Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA.Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes.Future directions for drug transporter modelling.Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption.In vitro-in vivo correlation of efavirenz tablets using GastroPlus®Understanding the effect of API properties on bioavailability through absorption modeling.Pediatric Biopharmaceutical Classification System: Using Age-Appropriate Initial Gastric Volume.Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugsComparative in vitro dissolution study of carbamazepine immediate-release products using the USP paddles method and the flow-through cell system.Overview of drug product development.Ultrasound-induced cell permeabilisation and hyperthermia: strategies for local delivery of compounds with intracellular mode of action.Preparation, characterization, stability and in vitro-in vivo evaluation of pellet-layered Simvastatin nanosuspensions.Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems.Inorganic matrices: an answer to low drug solubility problem.Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems.The role of formulation on the pharmacokinetics of antiretroviral drugs.Helicobacter pylori infection and drugs malabsorption.Oral bioavailability: issues and solutions via nanoformulations.Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.The Precipitation Behavior of Poorly Water-Soluble Drugs with an Emphasis on the Digestion of Lipid Based Formulations.In silico and in vitro prediction of gastrointestinal absorption from potential drug eremantholide C.Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.
P2860
Q24612643-01E57AD0-0B8A-4963-BB59-9C2C00EA6347Q28486428-AEAB7570-DD2F-4E63-AE77-04C2E814D635Q28551006-78DE5B1D-2CC8-4EC1-9EA7-4E9A3271A7F3Q33563610-224A3BAE-7683-4221-AA03-F3522481B6AEQ33755520-0F66B825-A3B8-473B-ADA9-380D11DE794EQ33954607-B6265669-6BC8-43F0-B549-99BFE66392B3Q34358839-DA3D3C91-67B0-49DE-93D2-64206BB67B93Q34833273-4BCFDF8E-EDCB-4B32-809D-4F06DA1C1D62Q35176797-4B0AD4A1-4EE0-4661-B629-E79CCD8C51E1Q35197162-5180528F-5A09-494F-83AD-0923200E7287Q35596511-ADD6AC24-34A1-44B4-A7A5-1FD5B8554A5EQ35607817-92A4928C-C432-4C3B-B249-10E634F0CAF1Q35768084-03060112-501B-4D66-B7FF-9DC87A400EBBQ35849309-0F9B9E4D-A581-4EF4-BA73-E7620BB2C4E0Q35868312-A27BF68E-02B0-442A-97C5-8E5E7A6322D4Q35868332-30A0C0A1-E91C-4058-AC67-A06AC2A2261DQ35868365-CE5B4BFA-94A7-4738-9C01-594AB1F73541Q35982999-18A723EE-96C8-4980-A0F7-0DC963D88698Q36331520-55C2DEFA-D223-477B-91A4-4B65010AEE64Q36390234-36D7AC3F-3E30-4742-9EFE-F3C18CE12838Q36985072-5C7015B4-BA26-432C-A035-F6E8C6C0FE6FQ37058658-E273D047-97A5-431B-9D68-E44C92254040Q37126427-B79F3EB2-8C18-48FB-BF34-DD37A901441AQ37323446-08350B79-661D-4B45-A39E-B80500F26A41Q37600374-F635577B-E81E-441B-A51C-25059222FAEBQ37624491-F49FCF23-0D84-410C-AE1F-697FAB15F7C7Q37631534-FA1E22CB-3B21-4AD5-B79B-8FECB01A1C97Q37965423-33EC4D9E-F374-4092-ADE3-73054C73147FQ38012536-17B3B477-2DC1-4877-BB17-7AF2F4D72152Q38050511-8E44BBCD-08BD-47E7-81FD-9FFF6BE657B7Q38051448-3D0F08DA-660E-4DA3-A6BC-8074CF59EBF6Q38051672-4405B5FC-4D77-41AF-B013-A6F85CA17F3FQ38181489-3F0C63D6-F006-44AA-AD78-AC97CEF7B22CQ38216047-68095A3C-CD79-4569-87E7-A3EF09963267Q38240844-57D30282-B945-4EC2-8D6A-6AF9184C47D9Q38349734-498F871E-8A3B-4A11-BE09-C0D5DCD37F10Q38548995-B3E2B912-9EAC-43C4-B1E7-781F7CFA801CQ38644728-32A93B63-2873-4C9F-A8D9-3F040416CF7DQ38672619-24CBE55F-1EEA-4BAE-9586-BD1162904F5CQ38865422-E747AC2D-C227-435E-9AC9-C3D7496B119B
P2860
Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Classification of orally admin ...... ceutics classification system.
@ast
Classification of orally admin ...... ceutics classification system.
@en
type
label
Classification of orally admin ...... ceutics classification system.
@ast
Classification of orally admin ...... ceutics classification system.
@en
prefLabel
Classification of orally admin ...... ceutics classification system.
@ast
Classification of orally admin ...... ceutics classification system.
@en
P2093
P1476
Classification of orally admin ...... ceutics classification system.
@en
P2093
Jennifer B Dressman
Marc Lindenberg
Sabine Kopp
P304
P356
10.1016/J.EJPB.2004.03.001
P407
P577
2004-09-01T00:00:00Z